2009
Ovarian Preservation and Staging in Reproductive-Age Endometrial Cancer Patients
Richter C, Qian B, Martel M, Yu H, Azodi M, Rutherford T, Schwartz P. Ovarian Preservation and Staging in Reproductive-Age Endometrial Cancer Patients. Obstetrical & Gynecological Survey 2009, 64: 726-727. DOI: 10.1097/01.ogx.0000361368.51892.57.Peer-Reviewed Original ResearchDisease-free survivalLonger disease-free survivalSurgical stagingEndometrial cancerOvarian preservationClinical stagingPremenopausal womenEndometrial carcinomaEarly-stage low-grade endometrial cancerEarly-stage endometrial cancerEarly-stage endometrial carcinomaLow-grade endometrial cancerYoung womenLong-term adverse effectsAggressive surgical stagingGrade 1 diseaseStage endometrial cancerEndometrial cancer patientsStage 1 diseaseTotal abdominal hysterectomyEarly-stage patientsLonger overall survivalLarge university hospitalQuality of lifeParaaortic lymphadenectomy
1995
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaOvarian carcinomaMutant p53 proteinResidual tumorHistologic gradeOvarian cancerP53 proteinCancer relapseMutant p53 protein overexpressionLonger disease-free survivalKaplan-Meier survival curvesPostsurgical residual tumorDisease-free survivalEarly-stage diseaseSubset of patientsLow histologic gradeMutant p53 protein accumulationAdvanced-stage cancerDifferent clinical stagesP53-negative tumorsP53-positive tumorsP53 protein overexpressionPoor patient outcomesAnti-p53 antibodiesP53 protein accumulation